M.KrasniqiD.GittingerJ
No claims are made or implied regarding weight loss, metabolic benefits, therapeutic results, or human use
the agency also set deadlines by which compounding pharmacies would have to stop producing compounded GLP-1s under this rationale
The CV safety of a lower dose of liraglutide (1.8 mg, Victoza, Novo Nordisk) in people with T2D was established in the Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results (LEADER) study, showing a 13% reduction in major CV events over an average of 3.8 years [44]
They also run on a dosing schedule that doesn't pause just because you've crossed into a different time zone or are mid-flight somewhere over Europe
In trials, dosing was administered as a once-weekly subcutaneous injection, with gradual dose titration to minimise gastrointestinal side effects whilst allowing the body to adapt